Rare diseases
Expansion into new international biotech markets can be challenging. Unfamiliar regulations and licensing, coupled with language and cultural differences, can all be barriers to growth. If you’re considering venturing into Europe and beyond, our easy-to-follow guides, shaped by 30 years of expertise in the rare disease market, will assist you in navigating challenges and gaining a profound understanding of the complexities involved in launching orphan drugs into new markets. To learn more about how Sciensus can facilitate and support your Europan expansion, visit: Rare Diseases and Orphan Drugs

Blogs
EMA orphan drug designation

Blogs
Four considerations before collecting real-world data in your EAP

Blogs
The increasing importance of real-world data for the EMA

Blogs
Real-world data and shaping the future of healthcare

Blogs
Six steps for a successful Early Access Program in Europe

Thought Leadership
Get the free whitepaper: Transitioning from open-label extensions to early access programs

Blogs
Mitigating risks in early access programs: A guide for biotech companies

Thought Leadership
Get the free whitepaper: How early access programs & real-world data help Biotechs succeed

News
Sciensus partners with Sentynl Therapeutics